Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial

被引：43
作者：
Trifan, Anca [1 ]
Burta, Ovidiu [2 ]
Tiuca, Nicoleta [3 ]
Petrisor, Diana Corina [4 ]
Lenghel, Augustin [5 ]
Santos, Javier [6 ]
机构：
[1] SC Gastromed SRL, Iasi, Romania
[2] Municipal Hosp Dr Gavril Curteanu, Dept Internal Med, Oradea, Romania
[3] Univ Emergency Hosp, Dept Internal Med, Bucharest, Romania
[4] Endodigest Med Clin, Oradea, Romania
[5] CMI Augustin Lenghel, Oradea, Romania
[6] Univ Hosp Vall dHebron, Digest Syst Res Unit, Barcelona, Spain
来源：
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL | 2019年 / 7卷 / 08期
关键词：
Diarrhoea-predominant irritable bowel syndrome; Gelsectan; pea protein and tannins; prebiotics; mucoprotectants; xyloglucan; xylo-oligosaccharide; QUALITY-OF-LIFE; DIAGNOSIS;
D O I：
10.1177/2050640619862721
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Background Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier. Objective The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea-predominant IBS (IBS-D). Methods In this double-blind study, 60 patients were randomly assigned to receive XG + PPT + XOS or placebo for 28 days, then crossed over to the alternative treatment. Patients were followed for 60 days. Results At Day 28, a significantly higher proportion of patients starting treatment with XG + PPT + XOS than placebo (87 vs 0%; p = 0.0019) presented normal stools (Bristol Stool Form Scale type 3-4). At Day 56, a significantly higher proportion of patients who crossed over to XG + PPT + XOS than placebo (93% vs 23%; p = 0.0001) presented normal stools. In the group allocated to receive XG + PPT + XOS after placebo, benefits of XG + PPT + XOS were maintained during follow-up. Subjective assessments of abdominal pain, bloating, quality of life and general health indicated significant improvement with XG + PPT + XOS over placebo. There were no related adverse events. Conclusion XG + PPT + XOS effectively controlled diarrhoea and alleviated clinical symptoms in patients with IBS-D, and was well tolerated.
引用
收藏
页码：1093 / 1101
页数：9
相关论文
共 50 条
[31]   Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study [J].
Bearcroft, CP ;
Perrett, D ;
Farthing, MJG .
GUT, 1998, 42 (01) :42-46
[32]   Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial [J].
Flik, Carla E. ;
Laan, Wijnand ;
Zuithoff, Nicolaas P. A. ;
van Rood, Yanda R. ;
Smout, Andre J. P. M. ;
Weusten, Bas L. A. M. ;
Whorwell, Peter J. ;
de Wit, Niek J. .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (01) :20-31
[33]   Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways [J].
Qiuke Hou ;
Yongquan Huang ;
Zhaoyang Zhu ;
Liu Liao ;
Xinlin Chen ;
Quanbin Han ;
Fengbin Liu .
BMC Complementary and Alternative Medicine, 19
[34]   Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways [J].
Hou, Qiuke ;
Huang, Yongquan ;
Zhu, Zhaoyang ;
Liao, Liu ;
Chen, Xinlin ;
Han, Quanbin ;
Liu, Fengbin .
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 19 (01)
[35]   Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial [J].
Chey, William D. ;
Lembo, Anthony J. ;
Rosenbaum, David P. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (05) :763-774
[36]   Effect of combined consumption of Lactobacillus brevis KB290 and -carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial [J].
Fuke, Nobuo ;
Aizawa, Koichi ;
Suganuma, Hiroyuki ;
Takagi, Tomohisa ;
Naito, Yuji .
INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2017, 68 (08) :973-986
[37]   Shared decision-making improving efficacy in diarrhoea-dominant irritable bowel syndrome in Chinese outpatient setting: protocol of a prospective, randomised controlled trial [J].
Song, Kai ;
Fan, Zhengyang ;
Chen, Yang ;
Fei, Guijun ;
Li, Xiaoqing ;
Wu, Dong .
BMJ OPEN, 2023, 13 (12)
[38]   Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D [J].
Anton Emmanuel ;
Richard William Goosey ;
Gwen Wiseman ;
Stephen Baker ;
Hans Törnblom .
BMC Gastroenterology, 20
[39]   Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial [J].
Kim, Joong Il ;
Kim, Pumsoo ;
Lee, Jin-Hyun ;
Kim, Yoo-Jin ;
Yang, Na-rae ;
Baeg, Myong Ki ;
Choi, Ja Sung ;
Kim, Hye-Jung ;
Kim, Jayoung ;
Sunwoo, Yun-Young ;
Lee, Jung-Han ;
Ha, Hyekyung ;
Park, Tae-Yong .
BMJ OPEN, 2017, 7 (11)
[40]   Observation of the clinical efficacy of moxa-stick moxibustion in treating diarrhea-predominant irritable bowel syndrome [J].
Ma, Jindan ;
Li, Guona ;
Sun, Fangyuan ;
Qi, Qin ;
Wu, Luyi ;
Zhao, Chen ;
Liu, Huirong ;
Lu, Yuan ;
Ma, Xiaopeng ;
Chen, Liming ;
Wang, Zhaoqin ;
Zhou, Cili ;
Wu, Huangan .
JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, 2025, 23 (02) :135-143
12345